Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
Identifieur interne : 000373 ( Main/Exploration ); précédent : 000372; suivant : 000374Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
Auteurs : Irina Panovska-Stavridis ; Nevenka Ridova ; Tatjana Stojanoska ; Ilir Demiri ; Milena Stevanovic ; Simona Stojanovska ; Tara Ristevska ; Aleksandar Dimkovski ; Venko Filipce ; Aleksandar Dimovski ; Aleksandra GrozdanovaSource :
- Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) [ 1857-8985 ] ; 2021.
Descripteurs français
- KwdFr :
- AMP (analogues et dérivés), AMP (usage thérapeutique), Alanine (analogues et dérivés), Alanine (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antiviraux (usage thérapeutique), Association médicamenteuse (MeSH), Chloroquine (usage thérapeutique), Dexaméthasone (usage thérapeutique), Essais cliniques comme sujet (MeSH), Facteurs immunologiques (usage thérapeutique), Glucocorticoïdes (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Immunisation passive (MeSH), Lopinavir (usage thérapeutique), Ritonavir (usage thérapeutique).
- MESH :
- analogues et dérivés : AMP, Alanine.
- usage thérapeutique : AMP, Alanine, Anticorps monoclonaux humanisés, Antiviraux, Chloroquine, Dexaméthasone, Facteurs immunologiques, Glucocorticoïdes, Hydroxychloroquine, Lopinavir, Ritonavir.
- Association médicamenteuse, Essais cliniques comme sujet, Humains, Immunisation passive.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Alanine (analogs & derivatives), Alanine (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), COVID-19 (therapy), Chloroquine (therapeutic use), Clinical Trials as Topic (MeSH), Dexamethasone (therapeutic use), Drug Combinations (MeSH), Glucocorticoids (therapeutic use), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunization, Passive (MeSH), Immunologic Factors (therapeutic use), Lopinavir (therapeutic use), Ritonavir (therapeutic use), SARS-CoV-2 (MeSH).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Antibodies, Monoclonal, Humanized, Antiviral Agents, Chloroquine, Dexamethasone, Glucocorticoids, Hydroxychloroquine, Immunologic Factors, Lopinavir, Ritonavir.
- drug therapy : COVID-19.
- therapy : COVID-19.
- Clinical Trials as Topic, Drug Combinations, Humans, Immunization, Passive, SARS-CoV-2.
Abstract
The outbreak of the COVID-19 pandemic has generated the largest global health crisis of the 21st century, evolving into accelerating socioeconomic disruption. In spite of all rapidly and widely emerging scientific data on epidemiology, diagnosis, prevention and treatment of the COVID-19 disease, severe acute respiratory coronavirus 2 (SARS-CoV-2) is continuing to propagate in lack of definitive and specific therapeutic agents. Current therapeutic strategies are mainly focused on viral inhibition by antiviral drugs and hampering the exuberant immune response of the host by immunomodulatory drugs. In this review, we have studied the reports of the largest clinical trials intended to COVID-19 treatment published during the first year of the pandemics. In general, these results concentrate on seven therapeutic options: remdesivir, chloroguine/hydroxychloroquine, lopinavir-ritonavir combination, corticosteroids, tocilizumab, convalescent plasma and monoclonal antibodies. In line with the reviewed data, as of January 2021, most of the evidence support the use of remdesivir in hospitalized patients with moderate and severe forms of the disease and provide reliable data on the substantial beneficial effect of corticosteroids in patients requiring supplemental oxygen. Moreover, preliminary RECOVERY trial results have demonstrated the efficacy of tociluzumab in the treatment of critically ill patients. The reports presenting the outcomes of the other immune-based therapies under investigation are enthusiastically awaited.
DOI: 10.2478/prilozi-2021-0001
PubMed: 33894123
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).</title><author><name sortKey="Panovska Stavridis, Irina" sort="Panovska Stavridis, Irina" uniqKey="Panovska Stavridis I" first="Irina" last="Panovska-Stavridis">Irina Panovska-Stavridis</name><affiliation><nlm:affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Ridova, Nevenka" sort="Ridova, Nevenka" uniqKey="Ridova N" first="Nevenka" last="Ridova">Nevenka Ridova</name><affiliation><nlm:affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Stojanoska, Tatjana" sort="Stojanoska, Tatjana" uniqKey="Stojanoska T" first="Tatjana" last="Stojanoska">Tatjana Stojanoska</name><affiliation><nlm:affiliation>University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Demiri, Ilir" sort="Demiri, Ilir" uniqKey="Demiri I" first="Ilir" last="Demiri">Ilir Demiri</name><affiliation><nlm:affiliation>University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Stevanovic, Milena" sort="Stevanovic, Milena" uniqKey="Stevanovic M" first="Milena" last="Stevanovic">Milena Stevanovic</name><affiliation><nlm:affiliation>University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Stojanovska, Simona" sort="Stojanovska, Simona" uniqKey="Stojanovska S" first="Simona" last="Stojanovska">Simona Stojanovska</name><affiliation><nlm:affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Ristevska, Tara" sort="Ristevska, Tara" uniqKey="Ristevska T" first="Tara" last="Ristevska">Tara Ristevska</name><affiliation><nlm:affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Dimkovski, Aleksandar" sort="Dimkovski, Aleksandar" uniqKey="Dimkovski A" first="Aleksandar" last="Dimkovski">Aleksandar Dimkovski</name><affiliation><nlm:affiliation>Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Filipce, Venko" sort="Filipce, Venko" uniqKey="Filipce V" first="Venko" last="Filipce">Venko Filipce</name><affiliation><nlm:affiliation>University Clinic for Neurosurgery, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Dimovski, Aleksandar" sort="Dimovski, Aleksandar" uniqKey="Dimovski A" first="Aleksandar" last="Dimovski">Aleksandar Dimovski</name><affiliation><nlm:affiliation>Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Research Center for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Sciences and Arts, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Grozdanova, Aleksandra" sort="Grozdanova, Aleksandra" uniqKey="Grozdanova A" first="Aleksandra" last="Grozdanova">Aleksandra Grozdanova</name><affiliation><nlm:affiliation>Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33894123</idno><idno type="pmid">33894123</idno><idno type="doi">10.2478/prilozi-2021-0001</idno><idno type="wicri:Area/Main/Corpus">000086</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000086</idno><idno type="wicri:Area/Main/Curation">000086</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000086</idno><idno type="wicri:Area/Main/Exploration">000086</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).</title><author><name sortKey="Panovska Stavridis, Irina" sort="Panovska Stavridis, Irina" uniqKey="Panovska Stavridis I" first="Irina" last="Panovska-Stavridis">Irina Panovska-Stavridis</name><affiliation><nlm:affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Ridova, Nevenka" sort="Ridova, Nevenka" uniqKey="Ridova N" first="Nevenka" last="Ridova">Nevenka Ridova</name><affiliation><nlm:affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Stojanoska, Tatjana" sort="Stojanoska, Tatjana" uniqKey="Stojanoska T" first="Tatjana" last="Stojanoska">Tatjana Stojanoska</name><affiliation><nlm:affiliation>University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Demiri, Ilir" sort="Demiri, Ilir" uniqKey="Demiri I" first="Ilir" last="Demiri">Ilir Demiri</name><affiliation><nlm:affiliation>University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Stevanovic, Milena" sort="Stevanovic, Milena" uniqKey="Stevanovic M" first="Milena" last="Stevanovic">Milena Stevanovic</name><affiliation><nlm:affiliation>University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Stojanovska, Simona" sort="Stojanovska, Simona" uniqKey="Stojanovska S" first="Simona" last="Stojanovska">Simona Stojanovska</name><affiliation><nlm:affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Ristevska, Tara" sort="Ristevska, Tara" uniqKey="Ristevska T" first="Tara" last="Ristevska">Tara Ristevska</name><affiliation><nlm:affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Dimkovski, Aleksandar" sort="Dimkovski, Aleksandar" uniqKey="Dimkovski A" first="Aleksandar" last="Dimkovski">Aleksandar Dimkovski</name><affiliation><nlm:affiliation>Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Filipce, Venko" sort="Filipce, Venko" uniqKey="Filipce V" first="Venko" last="Filipce">Venko Filipce</name><affiliation><nlm:affiliation>University Clinic for Neurosurgery, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Dimovski, Aleksandar" sort="Dimovski, Aleksandar" uniqKey="Dimovski A" first="Aleksandar" last="Dimovski">Aleksandar Dimovski</name><affiliation><nlm:affiliation>Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Research Center for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Sciences and Arts, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author><author><name sortKey="Grozdanova, Aleksandra" sort="Grozdanova, Aleksandra" uniqKey="Grozdanova A" first="Aleksandra" last="Grozdanova">Aleksandra Grozdanova</name><affiliation><nlm:affiliation>Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</nlm:affiliation><wicri:noCountry code="subField">Republic of North Macedonia</wicri:noCountry></affiliation></author></analytic><series><title level="j">Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)</title><idno type="eISSN">1857-8985</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Adenosine Monophosphate (therapeutic use)</term><term>Alanine (analogs & derivatives)</term><term>Alanine (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (therapy)</term><term>Chloroquine (therapeutic use)</term><term>Clinical Trials as Topic (MeSH)</term><term>Dexamethasone (therapeutic use)</term><term>Drug Combinations (MeSH)</term><term>Glucocorticoids (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunization, Passive (MeSH)</term><term>Immunologic Factors (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Ritonavir (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term><term>AMP (usage thérapeutique)</term><term>Alanine (analogues et dérivés)</term><term>Alanine (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Association médicamenteuse (MeSH)</term><term>Chloroquine (usage thérapeutique)</term><term>Dexaméthasone (usage thérapeutique)</term><term>Essais cliniques comme sujet (MeSH)</term><term>Facteurs immunologiques (usage thérapeutique)</term><term>Glucocorticoïdes (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Immunisation passive (MeSH)</term><term>Lopinavir (usage thérapeutique)</term><term>Ritonavir (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Antibodies, Monoclonal, Humanized</term><term>Antiviral Agents</term><term>Chloroquine</term><term>Dexamethasone</term><term>Glucocorticoids</term><term>Hydroxychloroquine</term><term>Immunologic Factors</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term><term>Alanine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term><term>Alanine</term><term>Anticorps monoclonaux humanisés</term><term>Antiviraux</term><term>Chloroquine</term><term>Dexaméthasone</term><term>Facteurs immunologiques</term><term>Glucocorticoïdes</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Drug Combinations</term><term>Humans</term><term>Immunization, Passive</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association médicamenteuse</term><term>Essais cliniques comme sujet</term><term>Humains</term><term>Immunisation passive</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The outbreak of the COVID-19 pandemic has generated the largest global health crisis of the 21st century, evolving into accelerating socioeconomic disruption. In spite of all rapidly and widely emerging scientific data on epidemiology, diagnosis, prevention and treatment of the COVID-19 disease, severe acute respiratory coronavirus 2 (SARS-CoV-2) is continuing to propagate in lack of definitive and specific therapeutic agents. Current therapeutic strategies are mainly focused on viral inhibition by antiviral drugs and hampering the exuberant immune response of the host by immunomodulatory drugs. In this review, we have studied the reports of the largest clinical trials intended to COVID-19 treatment published during the first year of the pandemics. In general, these results concentrate on seven therapeutic options: remdesivir, chloroguine/hydroxychloroquine, lopinavir-ritonavir combination, corticosteroids, tocilizumab, convalescent plasma and monoclonal antibodies. In line with the reviewed data, as of January 2021, most of the evidence support the use of remdesivir in hospitalized patients with moderate and severe forms of the disease and provide reliable data on the substantial beneficial effect of corticosteroids in patients requiring supplemental oxygen. Moreover, preliminary RECOVERY trial results have demonstrated the efficacy of tociluzumab in the treatment of critically ill patients. The reports presenting the outcomes of the other immune-based therapies under investigation are enthusiastically awaited.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33894123</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1857-8985</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>23</Day></PubDate></JournalIssue><Title>Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)</Title><ISOAbbreviation>Pril (Makedon Akad Nauk Umet Odd Med Nauki)</ISOAbbreviation></Journal><ArticleTitle>Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).</ArticleTitle><Pagination><MedlinePgn>5-18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2478/prilozi-2021-0001</ELocationID><Abstract><AbstractText>The outbreak of the COVID-19 pandemic has generated the largest global health crisis of the 21st century, evolving into accelerating socioeconomic disruption. In spite of all rapidly and widely emerging scientific data on epidemiology, diagnosis, prevention and treatment of the COVID-19 disease, severe acute respiratory coronavirus 2 (SARS-CoV-2) is continuing to propagate in lack of definitive and specific therapeutic agents. Current therapeutic strategies are mainly focused on viral inhibition by antiviral drugs and hampering the exuberant immune response of the host by immunomodulatory drugs. In this review, we have studied the reports of the largest clinical trials intended to COVID-19 treatment published during the first year of the pandemics. In general, these results concentrate on seven therapeutic options: remdesivir, chloroguine/hydroxychloroquine, lopinavir-ritonavir combination, corticosteroids, tocilizumab, convalescent plasma and monoclonal antibodies. In line with the reviewed data, as of January 2021, most of the evidence support the use of remdesivir in hospitalized patients with moderate and severe forms of the disease and provide reliable data on the substantial beneficial effect of corticosteroids in patients requiring supplemental oxygen. Moreover, preliminary RECOVERY trial results have demonstrated the efficacy of tociluzumab in the treatment of critically ill patients. The reports presenting the outcomes of the other immune-based therapies under investigation are enthusiastically awaited.</AbstractText><CopyrightInformation>© 2021 Irina Panovska-Stavridis et al., published by Sciendo.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Panovska-Stavridis</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ridova</LastName><ForeName>Nevenka</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stojanoska</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demiri</LastName><ForeName>Ilir</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevanovic</LastName><ForeName>Milena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Clinic of Infection Diseases and Febrile Conditions, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stojanovska</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ristevska</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University Clinic of Hematology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimkovski</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filipce</LastName><ForeName>Venko</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>University Clinic for Neurosurgery, Faculty of Medicine, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimovski</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center for Genetic Engineering and Biotechnology "Georgi D. Efremov", Macedonian Academy of Sciences and Arts, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grozdanova</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, University Ss. Cyril and Methodius, Skopje, Republic of North Macedonia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>North Macedonia</Country><MedlineTA>Pril (Makedon Akad Nauk Umet Odd Med Nauki)</MedlineTA><NlmUniqueID>101677081</NlmUniqueID><ISSNLinking>1857-9345</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral drugs</Keyword><Keyword MajorTopicYN="N">immunomodulatory drugs</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>24</Day><Hour>17</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33894123</ArticleId><ArticleId IdType="pii">prilozi-2021-0001</ArticleId><ArticleId IdType="doi">10.2478/prilozi-2021-0001</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>1. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020 Mar 13; 27(2): taaa021.</Citation></Reference><Reference><Citation>2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. 2020; 5(4): 536–544.</Citation></Reference><Reference><Citation>3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20; 382(8): 727–733.</Citation></Reference><Reference><Citation>4. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020 Mar 19;91(1):157-160.</Citation></Reference><Reference><Citation>5. Gilbert GL. Commentary: SARS, MERS and COVID-19-new threats; old lessons. Int J Epidemiol. 2020 Jun 1; 49(3): 726–728.</Citation></Reference><Reference><Citation>6. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARSCoV-2 by full-length human ACE2. Science. 2020 March 27; 367(6485): 1444–1448.</Citation></Reference><Reference><Citation>7. Gupta, A., Madhavan, M.V., Sehgal, K. et al. Extrapulmonary manifestations of COVID-19. Nat Med 26, 1017–1032 (2020).</Citation></Reference><Reference><Citation>8. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020; 92(4): 418–23.</Citation></Reference><Reference><Citation>9. European Medicine Agency [EMA]. COVID-19 latest updates. 12 January 2021. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19 (Date accessed: 13 January 2021).</Citation></Reference><Reference><Citation>10. RECOVERY Collaborative Group, Horby P, Mafham M, et al.; Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Nov 19; 383(21): 2030–2040.</Citation></Reference><Reference><Citation>11. RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 5; 396(10259): 1345–52.</Citation></Reference><Reference><Citation>12. RECOVERY Collaborative Group, Horby P, Lim WS et al; Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report. N Engl J Med. 2020 Jul 17: NEJMoa2021436.</Citation></Reference><Reference><Citation>13. Peter W Horby, Mark Campbell et al; Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial, medRxiv 2021.02.11.21249258</Citation></Reference><Reference><Citation>14. WHO Solidarity Trial Consortium, Pan H, et al. Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. N Engl J Med. 2020 Dec 2: NEJMoa2023184.</Citation></Reference><Reference><Citation>15. Ader F; Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ Open. 2020; 10(9): e041437. Published 2020 Sep 21.</Citation></Reference><Reference><Citation>16. Halimi, V., Daci, A., Ridova, N. et al. The use of remdesivir outside of clinical trials during the COVID-19 pandemic. J of Pharm Policy and Pract13, 61 (2020).</Citation></Reference><Reference><Citation>17. Halimi V, Daci A, Stojanovska S, Panovska-Stavridis I, Stevanovic M, Filipce V, Grozdanova A. Current regulatory approaches for accessing potential COVID-19 therapies. J Pharm Policy Pract. 2020 May 16;13:16.</Citation></Reference><Reference><Citation>18. Kaur, H., Shekhar, N., Sharma, S. et al. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol. Rep (2021).</Citation></Reference><Reference><Citation>19. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016: Mar 17;531(7594): 381–5.</Citation></Reference><Reference><Citation>20. Mulangu S, Dodd LE, Davey RT, Jr, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. The New England journal of medicine. 2019; Dec 12; 381(24): 2293–2303.</Citation></Reference><Reference><Citation>21. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017. Jun 28; 9 (396): eaal3653.</Citation></Reference><Reference><Citation>22. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature communications. 2020 Jan 10; 11(1): 222.</Citation></Reference><Reference><Citation>23. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020 Mar; 30(3): 269–271.</Citation></Reference><Reference><Citation>24. S.A. Kujawski, K.K. Wong, J.P. Collins, et al. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States. medRxiv (2020).</Citation></Reference><Reference><Citation>25. J. Grein, N. Ohmagari, D. Shin, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020 Jun 11; 382: 2327–36.</Citation></Reference><Reference><Citation>26. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395 (10236): 1569–78.</Citation></Reference><Reference><Citation>27. Beigel JH, Tomashek KM,et.al; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 Nov 5; 383(19): 1813–1826.</Citation></Reference><Reference><Citation>28. Spinner CD, Gottlieb RL, et.al; Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 Sep 15; 324(11): 1048–1057.</Citation></Reference><Reference><Citation>29. Goldman JD, Lye DCB, et.al; Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 Nov 5; 383(19): 1827–1837.</Citation></Reference><Reference><Citation>30. Food and Drug Administration [FDA]. Corona-virus (COVID-19) Update: FDA Approves First Treatment For COVID-19. 22 October 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 (Date accessed 30 November 2020).</Citation></Reference><Reference><Citation>31. World Health Organization [WHO] WHO recommends against the use of remdesivir in COVID-19 patients. https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients (Date accessed 30 November 2020).</Citation></Reference><Reference><Citation>32. National Institutes for Health [NIH]. NIH clinical trial testing antiviral remdesivir plus anti-inflammatory drug baricitinib for COVID-19 begins. 08 May 2020. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-testing-antiviral-remdesivir-plus-anti-inflammatory-drug-baricitinib-covid-19-begins (Date acessed: 28 November 2020).</Citation></Reference><Reference><Citation>33. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends. 2020 Mar 16; 14(1): 72–73.</Citation></Reference><Reference><Citation>34. Biot C, Daher W, Chavain N, et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. Journal of medicinal chemistry. 2006; 49(9): 2845–2849.</Citation></Reference><Reference><Citation>35. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Jul 28; 71(15): 732–739.</Citation></Reference><Reference><Citation>36. P. Gautret, J.C. Lagier, P. Parola, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print] Int J Antimicrob Agents. 2020 Jul; 56(1); 105949.</Citation></Reference><Reference><Citation>37. Rosenke K, Jarvis MA, Feldmann F, et al. Hydroxychloroquine proves ineffective in hamsters and macaques infected with SARS-CoV 2. June 11, 2020 (https://www.biorxiv.org/content/10.1101/2020.06.10.145144v1). Preprint.</Citation></Reference><Reference><Citation>38. Skipper CP, Pastick KA, et.al; Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. Ann Intern Med. 2020 Oct 20; 173(8): 623–631.</Citation></Reference><Reference><Citation>39. Mitjà O, Corbacho-Monné M, et al.; BCN PEPCoV-2 RESEARCH GROUP. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. Clin Infect Dis. 2020 Jul 16:ciaa1009.</Citation></Reference><Reference><Citation>40. Ratia K, Pegan S, Takayama J, et al. A noncova-lent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(42): 16119–24.</Citation></Reference><Reference><Citation>41. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003; 9(6): 399–406.</Citation></Reference><Reference><Citation>42. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020 May 7; 382(19): 1787–1799.</Citation></Reference><Reference><Citation>43. Joshi S, Parkar J et al. Role of favipiravir in the treatment of COVID-19, International Journal of Infectious Diseases, 2021 Jan; 102: 501–508.</Citation></Reference><Reference><Citation>44. Ruan Q, Yang K, Wang W,et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020 May; 46(5): 846–848.</Citation></Reference><Reference><Citation>45. Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006; 129(6): 1441–1452.</Citation></Reference><Reference><Citation>46. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2004; 31(4): 304–309.</Citation></Reference><Reference><Citation>47. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. American journal of respiratory and critical care medicine. 2018; 197(6): 757–767.</Citation></Reference><Reference><Citation>48. Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020; 395(10225): 683–4.</Citation></Reference><Reference><Citation>49. Edalatifard M, Akhtari M et al; Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020 Sep 17:2002808.</Citation></Reference><Reference><Citation>50. Somers EC, Eschenauer GA, Troost JP, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clinical Infectious Diseases. 2020 Jul 11; ciaa954</Citation></Reference><Reference><Citation>51. Rossotti R, Travi G, Ughi et al, et al. Safety and efficacy of anti-IL6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis. J Infect 2020 Oct; 81(4): e11-e17</Citation></Reference><Reference><Citation>52. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8): e474-e484</Citation></Reference><Reference><Citation>53. Ivan Rosas, Norbert Bräu et al; Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia, medRxiv 2020.08.27.20183442.</Citation></Reference><Reference><Citation>54. Stone JH, Frigault MJ, et al; Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 Dec 10; 383(24): 2333–2344.</Citation></Reference><Reference><Citation>55. Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Apr; 20(4): 398–400.</Citation></Reference><Reference><Citation>56. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020; 324: 460–470.</Citation></Reference><Reference><Citation>57. Gharbharan A, Jordans CCE, Geurts van KesselC, et al. Convalescent plasma for COVID-19: a randomized clinical trial. July 3, 2020 (medrxiv 2020.07.01.20139857v1)</Citation></Reference><Reference><Citation>58. Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open-label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020; 371: m3939-m3939.</Citation></Reference><Reference><Citation>59. Simonovich VA, Burgos Pratx LD, et al; PlasmAr Study Group. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2020 Nov 24.</Citation></Reference><Reference><Citation>60. Weinreich DM et al; REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21; 384(3): 238–251.</Citation></Reference><Reference><Citation>61. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. (January 2021). “SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19”. The New England Journal of Medicine. 384 (3): 229–237.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Demiri, Ilir" sort="Demiri, Ilir" uniqKey="Demiri I" first="Ilir" last="Demiri">Ilir Demiri</name><name sortKey="Dimkovski, Aleksandar" sort="Dimkovski, Aleksandar" uniqKey="Dimkovski A" first="Aleksandar" last="Dimkovski">Aleksandar Dimkovski</name><name sortKey="Dimovski, Aleksandar" sort="Dimovski, Aleksandar" uniqKey="Dimovski A" first="Aleksandar" last="Dimovski">Aleksandar Dimovski</name><name sortKey="Filipce, Venko" sort="Filipce, Venko" uniqKey="Filipce V" first="Venko" last="Filipce">Venko Filipce</name><name sortKey="Grozdanova, Aleksandra" sort="Grozdanova, Aleksandra" uniqKey="Grozdanova A" first="Aleksandra" last="Grozdanova">Aleksandra Grozdanova</name><name sortKey="Panovska Stavridis, Irina" sort="Panovska Stavridis, Irina" uniqKey="Panovska Stavridis I" first="Irina" last="Panovska-Stavridis">Irina Panovska-Stavridis</name><name sortKey="Ridova, Nevenka" sort="Ridova, Nevenka" uniqKey="Ridova N" first="Nevenka" last="Ridova">Nevenka Ridova</name><name sortKey="Ristevska, Tara" sort="Ristevska, Tara" uniqKey="Ristevska T" first="Tara" last="Ristevska">Tara Ristevska</name><name sortKey="Stevanovic, Milena" sort="Stevanovic, Milena" uniqKey="Stevanovic M" first="Milena" last="Stevanovic">Milena Stevanovic</name><name sortKey="Stojanoska, Tatjana" sort="Stojanoska, Tatjana" uniqKey="Stojanoska T" first="Tatjana" last="Stojanoska">Tatjana Stojanoska</name><name sortKey="Stojanovska, Simona" sort="Stojanovska, Simona" uniqKey="Stojanovska S" first="Simona" last="Stojanovska">Simona Stojanovska</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000373 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000373 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33894123
|texte= Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33894123" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |